Agomelatine vs Phenibut

The EMA-approved dose for major depressive disorder is 25–50 mg/day (Valdoxan label); this is a regulatory fact, not a recommendation. Agomelatine is not FDA-approved in the United States, and no validated dosing exists for off-label or 'research' use. Absolute oral bioavailability is very low (commonly cited under 5%) due to extensive hepatic first-pass metabolism, primarily via CYP1A2 (~90%), with large interindividual variability. As a non-peptide small molecule, agomelatine does not require refrigeration, but gray-market bulk powder carries standard risks of unverified purity and identity.

No FDA-approved or trial-validated human dosing regimen exists. Case reports of dependence documented an average dose of 13.6 g/day (range 1.5–28.5 g/day), far exceeding typical supplement-label suggestions, with 73% of patients having a history of alcohol/drug abuse. Reported elimination half-life is approximately 5.3 hours (case-level data, not pooled pharmacokinetic study); excreted largely unchanged in urine. Phenibut is a non-peptide small molecule sold as powder or capsules; no special storage requirements are documented beyond standard dry/cool conditions.